Abstract
Background/Aim
Cholangiocarcinoma (CCA) is a malignant tumor with high mortality and recurrence rates after treatment. The discovery of prognostic markers is, therefore, essential for improving patient outcomes after treatment. This study aimed to investigate the prognostic value of membranous and cytoplasmic PD-L1 expression, individually and in combination. In addition, the combination of PD-L1 expression and chemotherapeutic status was also explored.
Patients and Methods
The expression of PD-L1 was examined in 200 CCA patients using immunohistological staining, and its correlation with clinicopathological data was investigated using the Chi-squared test. Overall survival (OS) and recurrence-free survival (RFS) investigations were performed using Kaplan-Meier (log-rank) and Cox-regression analysis.
Results
The results demonstrated that high PD-L1 expression in the membrane and low expression in the cytoplasm had a correlation with intrahepatic CCA and lymph node metastasis. Furthermore, these patients had shorter OS and RFS compared to other groups of patients. Moreover, when the expression of PD-L1 was combined with chemotherapeutic status, the result demonstrated that patients who had high expression of PD-L1 in the membrane with low expression of PD-L1 in the cytoplasm and did not receive adjuvant chemotherapy showed significantly shorter OS and RFS compared to other patients. This could be an independent prognostic factor for RFS and OS with HR 1.889 and 1.990, respectively.
Conclusion
PD-L1 expression levels can serve as a valuable predictor of outcomes in CCA patients, especially when evaluated alongside chemotherapeutic status.
Keywords: Cholangiocarcinoma, PD-L1, chemotherapy, prognostic marker, survival analysis
Introduction
Cholangiocarcinoma (CCA) is a malignant tumor that originates from the bile duct epithelium, accounting for 15% of primary hepatobiliary malignancies (1). The incidence of CCA varies geographically, but the highest incidence of CCA has been noted in Thailand, particularly in the northeastern region (2). Because CCA patients are mostly asymptomatic in the early stage, diagnosis is often made in advanced stages of disease resulting in poor outcomes for patients after treatment (2). Moreover, CCA patients also have high risk of recurrence, which can affect patients’ survival (3). Taken together, CCA is therefore a cancer with a high mortality rate. Identifying the markers that can predict cancer recurrence as well as patients’ survival is essential to improve patient outcomes after treatment.
Programmed death-ligand 1 (PD-L1), also known as B7-H1 (CD274), is a transmembrane glycoprotein encoded on chromosome nine (4). PD-L1 is expressed in several cell types, including hematopoietic, endothelial, and epithelial cells, and is expressed on tumor cells (5). In tumor cells, PD-L1 is believed to aid escape from immune cells by binding with PD-1 (4). Interaction between PD-L1 and PD-1 reduces the proliferation of PD-1 positive cells, inhibits cytokine secretion and induces apoptosis (6). In recent years, the PD-1/PD-L1 pathway has been a target for new anticancer therapies, and has improved patient survival in a number of cancers (7). Thus, investigation of PD-L1 expression and its correlation with clinical outcomes may be beneficial for treatment. In breast cancer, the expression of PD-L1 is correlated with the epithelial-to-mesenchymal transition (EMT) process in human breast cancer stem cells (BCSCs) (8). Additionally, an association between PD-L1 expression and clinicopathological data has been found in lung cancer. This report indicated that PD-L1 expression was positively correlated with male sex, advanced stage, invasion, and squamous cell carcinoma histology. PD-L1 positive patients had poorer outcomes than those in the negative group (9).
The prognostic value of PD-L1 has also been explored to some extent in CCA. One study used machine learning technology to investigate the prognostic value of PD-L1, with results suggesting PD-L1 positive patients had a worse prognosis than negative patients (10). Furthermore, several other studies have also demonstrated advantageous outcomes with low PD-L1 expression compared to high expression in terms of survival (11). There are, however, some studies that show high PD-L1 expression correlates with a good prognosis. Zhu and colleagues showed that PD-L1 overexpression was significantly correlated with good overall survival (OS) and disease-free survival (DFS) in CCA (5). In 2019, one study demonstrated that PD-L1 expression correlated with a lack of local invasion as well as improved survival (12). Many other studies indicated that PD-L1 level has no association with the survival of patients (7,13). Current research therefore presents a controversial picture of the prognostic value of PD-L1. Additionally, any benefits of examining PD-L1 expression in different CCA cell compartments are so far unknown. This study aimed to investigate the prognostic value of PD-L1 expression in cancer cell membranous and cytoplasm, individually and in combination.
Patients and Methods
Patients. Formalin-fixed paraffin-embedded tissues (FFPE) were obtained from CCA patients who had undergone surgery at the Srinagarind Hospital, Khon Kaen University, Thailand, between 2007 and 2016. Clinicopathological data were provided by the Cholangiocarcinoma Research Institute (CARI). Recurrence was defined as detection of a new tumor. Patients were excluded from the study if they received chemotherapy or radiotherapy before surgery to avoid potential effects on PD-L1 expression (14). The present study was approved by the Institutional Review Board of the Khon Kaen University Ethics Committee based on the Declaration of Helsinki (HE611412).
Immunohistochemistry (IHC). Tissue microarray (TMA) was prepared as 4 µm thick sections, with two independent punctures prepared for each patient. IHC staining was used to examine protein levels. Briefly, the sections were deparaffinized in xylene and rehydrated with a series of concentrations of ethanol. Antigen retrieval was performed using Tris-EDTA buffer in a pressure cooker. Endogenous hydrogen peroxide and nonspecific binding were blocked with 0.3% hydrogen peroxide and 10% skimmed milk. Primary antibody (PD-L1 rabbit monoclonal antibody, #13684, Cell Signaling Technology, Danvers, MA, USA) was incubated for 1 h at room temperature followed by 4˚C overnight. After washing, secondary antibody (Dako EnVision, Carpinteria, CA, USA) was added for 1 h. 3, 3’diaminobenzidine tetrahydrochloride (DAB) substrate kit (Vector Laboratories, Inc., Newark, CA, USA) was added to develop the signal, then counterstained with Mayer’s hematoxylin. Sections were dehydrated and mounted with Permount solution and observed under a light microscope (Nikon Ni-U, Tokyo, Japan).
IHC scoring system. Protein levels were recorded as frequency and intensity scores. Frequency was semi-qualitatively scored as the percentage of positive staining cells: 0%=negative, 1-25%=1+, 26-50%=2+, and >50%= 3+. The intensity scores were defined as 0 for negative staining, 1 for weak staining, 2 for moderate staining, and 3 for strong staining. The total score was calculated by multiplying the intensity and frequency. The results were classified as low expression if the score was less than the median and high expression if the score was more than the median.
Statistical analysis. The Statistical Package for the Social Sciences (SPSS) software was used for statistical analysis. The correlation between protein expression and clinicopathological features was determined using the Chi-square test. Overall survival (OS) and recurrence-free survival (RFS) were performed using Kaplan-Meier (log-rank) and Cox-regression analysis. A p-value less than 0.05 was considered statistically significant.
Results
Patient characteristics and the correlation with PD-L1 expression. Table I shows the patient characteristics and histopathology including sex, age, tumor location, histology, metastasis status, stage, and adjuvant chemotherapy status of patients. PD-L1 expression is shown in Figure 1. The correlation of PD-L1 expression with patients’ characteristics was analyzed based on location, either in cancer cell cytoplasm or membrane. Among 200 patients, 34.5% and 41.0% demonstrated high expression in the membrane or cytoplasm, respectively. Correlation between protein expression levels and clinicopathological features was also explored. In the membrane, high expression of PD-L1 was significantly associated with intrahepatic CCA (p=0.045), while high expression in the cytoplasm was significantly associated with extrahepatic CCA (p=0.014). However, when considering the expression in each part individually, there was no correlation between PD-L1 expression levels and other clinicopathological features, including sex, age, histology type, TNM stage, and recurrence. The combination of membranous and cytoplasmic expression was further examined. The results demonstrated that patients with high expression of PD-L1 in membrane and low expression in cytoplasm showed a correlation with intrahepatic CCA (p=0.010) and lymph node metastasis (p=0.033) (Table I).
Table I. Correlation between PD-L1 expression and clinicopathological features.
PD-L1: Programmed death-ligand 1; TNM: size of primary tumor-node metastasis-distant metastasis; Adjuvant CMT; adjuvant chemotherapy; C: cytoplasm; M: membrane. Statistically significant p-values are shown in bold.
Figure 1.
Representative figure of PD-L1 expression. (A) Low expression in the cytoplasm, (B) high expression in the cytoplasm, (C) low expression in the membrane, and (D) high expression in the membrane.
The correlation between PD-L1 expression in the membrane and the cytoplasm was also examined. The results indicated that patients with high PD-L1 expression in the membrane had low expression of PD-L1 in the cytoplasm (p=0.012).
PD-L1 expression and survival analysis. Survival rate was analyzed according to the expression levels of PD-L1. The results showed that patients with low expression of PD-L1 in the cytoplasm had significantly shorter overall survival (OS) (p=0.021) and recurrence-free survival (RFS) (p=0.005) compared to those with high expression (Figure 2A and B). In contrast, patients with high expression of PD-L1 in the membrane tend to have shorter OS and RFS compared with those with low expression (Figure 2C and D). Additionally, the combination of membranous and cytoplasmic expression was also investigated. The results showed that patients with high expression of PD-L1 in the membrane and low expression of PD-L1 in the cytoplasm showed significantly shorter OS (p=0.009) and RFS (p=0.009) compared with other groups of patients (Figure 2E and F).
Figure 2.
Survival analysis of PD-L1. (A) Overall survival and (B) Recurrence-free survival of CCA patients according to PD-L1 expression in the cytoplasm. (C) Overall survival and (D) Recurrence-free survival of CCA patients according to PD-L1 expression in the membrane, and (E) Overall survival and (F) Recurrence-free survival of CCA patients according to the combination of PD-L1 expression in the cytoplasm and membrane. CCA: Cholangiocarcinoma.
To identify an independent prognostic factor for OS and RFS, univariate and multivariate analyses were explored. The results from univariate analysis showed that the patients with high T stage (Stage III, IV), lymph node metastasis, and late stage showed unfavorable outcomes for OS and RFS. The hazard ratio (HR) of high T stage was 2.414 (p<0.001; RFS) and 2.480 (p<0.001; OS), lymph node metastasis was 2.001 (p<0.001; RFS) and 2.238 (p<0.001; OS), and late stage was 2.438 (p<0.001; RFS) and 2.639 (p<0.001; OS) compared with their references. While the HR of patients with high PD-L1 expression in the cytoplasm was 0.660 (p=0.005; RFS) and 0.714 (p=0.022; OS), for those with high expression of PD-L1 in membrane and low expression of PD-L1 in cytoplasm it was 1.546 (p=0.010; RFS) and 1.544 (p=0.010; OS) compared with their references (Table II). The results from multivariate analysis indicated that T stage and lymph node metastasis were independent prognostic factors of RFS and OS. The HR of the T stage was 1.679 (p=0.011; RFS) and 1.727 (p=0.006; OS) compared with their references. While the HR of lymph node metastasis was 1.546 (p=0.043; OS) compared with their references. However, there was no statistical significance in the PD-L1 expression on multivariate analysis (Table III).
Table II. Univariate analysis of PD-L1 expression.
PD-L1: Programmed death-ligand 1; TNM: size of primary tumor-node metastasis-distant metastasis; Adjuvant CMT: adjuvant chemotherapy; HR: hazard ratio; C: cytoplasm; M: membrane. Statistically significant p-values are shown in bold.
Table III. Multivariate analysis of PD-L1 expression.
PD-L1: Programmed death-ligand 1; TNM: size of primary/tumor-node metastasis/distant metastasis; Adjuvant CMT: adjuvant chemotherapy; HR: hazard ratio; C: cytoplasm; M: membrane. Statistically significant p-values are shown in bold.
Survival outcomes based on PD-L1 expression and adjuvant chemotherapy status. Patients’ survival was also analyzed according to adjuvant chemotherapy status. In patients who did not receive adjuvant chemotherapy, the result showed that the patients with high expression of PD-L1 in the membrane and low expression of PD-L1 in the cytoplasm showed significantly shorter OS (p=0.001) and RFS (p=0.002) compared with other groups of patients (Figure 3). In contrast, there was no statistical significance in patients who received adjuvant chemotherapy (data not shown).
Figure 3.
Survival analysis of CCA patients who did not receive chemotherapy. (A) Overall survival (B) recurrence-free survival of CCA patients according to the combination of PD-L1 expression in the cytoplasm and membrane. CCA: Cholangiocarcinoma.
Furthermore, survival analysis regarding the combination of PD-L1 expression and adjuvant chemotherapy status was also examined. Patients who had high expression of PD-L1 in the membrane and low expression of PD-L1 in the cytoplasm and did not receive adjuvant chemotherapy showed significantly shorter OS (p<0.001) and RFS (p<0.001) compared to other patients (Figure 4). To examine whether the combination of PD-L1 expression and adjuvant chemotherapy status could be used as a prognostic factor, univariate and multivariate analyses were examined. Univariate analysis showed the HR of patients who had high expression of PD-L1 in the membrane and low expression of PD-L1 in the cytoplasm and did not receive adjuvant chemotherapy was 2.022 (p=0.001; RFS) and 2.142 (p<0.001; OS) compared with their reference (Table II). Moreover, it could be used as an independent prognostic factor for RFS and OS with HR 1.889 (p=0.038; RFS) and 1.990 (p=0.022; OS), respectively (Table III).
Figure 4.
Survival analysis regarding the combination of PD-L1 expression and adjuvant chemotherapy status. (A) Overall survival (B) recurrence-free survival of CCA patients according to the combination of PD-L1 expression and adjuvant chemotherapy status. CCA: Cholangiocarcinoma.
Discussion
Cholangiocarcinoma is a cancer that is mostly asymptomatic in the early stages; thus, most patients are diagnosed when the disease becomes advanced (15). This results in a high mortality rate among these patients. Moreover, many patients experience recurrence after treatment, resulting in a poor prognosis associated with the disease (16). To solve this problem, identification of methods for early diagnosis as well as markers related to the patient’s prognosis after treatment are essential.
Programmed death-ligand 1 (PD-L1) is a transmembrane glycoprotein expressed in several cell types as well as in tumor cells (17). Interactions between PD-L1 and its receptor, PD-1, attenuate T cell-activating signals, such as inhibiting cytokine production, T cell proliferation, survival, etc. PD-L1 is thus believed to help cancer cells evade immune responses (18). Because of its role in T cell suppression, antibody-based cancer therapeutics have been developed to target PD-L1 (19). However, treatment with a PD-1/PD-L1 inhibitor can trigger immune-related adverse events (20). Knowing its role and its importance to patients’ prognoses is therefore beneficial before using it as a drug target. In 2019, the prognostic value of PD-L1 was examined in colorectal cancer using a systematic review and meta-analysis from ten studies. The results indicated that high expression of PD-L1 was significantly correlated with poor overall and disease-free survival. This suggests that the expression of PD-L1 might be a biomarker for a poor prognosis in patients with colorectal cancer (21). PD-L1 shows a broad distribution in many cellular compartments, including the cell membrane, cytoplasm, and nucleus, and can also be secreted into the circulation (22). Recently, there was a study that highlighted the importance of investigating PD-L1 expression in different compartments of endometrial cancer (EC). The results demonstrated that soluble PD-L1 is easily detectable and is associated with aggressive clinical features in EC patients (23). In our studies, we thus investigate the expression of PD-L1 in CCA tissues. The prognostic value of PD-L1 was examined based on its location, in either the cytoplasm or membrane. We found that high expression of PD-L1 in the membrane was associated with intrahepatic CCA. On the other hand, the high expression of PD-L1 in the cytoplasm was associated with extrahepatic CCA. Furthermore, the combination of membranous and cytoplasmic expression was also explored. The results showed that the combining of high expression of PD-L1 in the membranous part with low expression of PD-L1 in the cytoplasmic part was associated with intrahepatic CCA and lymph node metastasis. This result indicated that high expression of PD-L1 on the membrane was associated with more aggressive cancer. This may be associated with its function as a ligand of PD-1, as binding of PD-L1 and PD-1 leads to the suppression of T-cell-mediated immunity (18). Several studies have reported that the expression of PD-L1 is associated with the survival of cancer patients (7,24-27). Similarly in our study, we found CCA patients with low expression of PD-L1 in cytoplasm had significantly shorter OS and RFS than other groups. In contrast, patients with high expression of PD-L1 in the membrane tend to have shorter OS and RFS compared with those with low expression. These results indicate the importance of the location of PD-L1 expression, which can affect its correlation with survival (24,26).
Surgery can nowadays be a potentially curative treatment for CCA patients. However, most patients are diagnosed with CCA when the disease is in a late stage. Surgery is therefore not suitable for all patients (28). In addition to surgery, adjuvant chemotherapy or radiotherapy is beneficial and can improve a patient’s survival. Therefore, to avoid the effect of chemotherapy on patients’ outcomes, we analyzed the prognostic value of PD-L1 according to chemotherapy status (29). In patients who did not receive chemotherapy, we found that patients with high expression of PD-L1 in the membrane combined with low expression in the cytoplasm had shorter OS and RFS compared with other groups of patients, which we did not find in patients who received adjuvant chemotherapy. This indicates that the expression of PD-L1 might not affect the response to chemotherapy. Moreover, if the expression of PD-L1 levels was combined with chemotherapeutic status, it could serve as an independent prognostic marker for OS and RFS of CCA patients.
Conclusion
PD-L1 expression levels serve as a valuable predictor of outcomes in cholangiocarcinoma patients, especially when evaluated alongside chemotherapeutic status.
Conflicts of Interest
The Authors declare no conflicts of interest.
Authors’ Contributions
Conceptualization, S.P., M.T, W.L; analysis and interpretation of data, S.P., M.T; project administration, W.L; writing and editing manuscript, S.P., M.T, H.D., T.C., W.L. All Authors have read and agreed to the published version of the manuscript.
Acknowledgements
The Authors are grateful to the Faculty of Medicine, Khon Kaen University, and the Cholangiocarcinoma Research Institute, Thailand, for supporting the study.
Funding
The study was supported the grant of the National Research Council of Thailand through Fluke Free Thailand Project and the Basic Research Fund of Khon Kaen University under Cholangiocarcinoma Research Institute to WL.
Artificial Intelligence (AI) Disclosure
No artificial intelligence (AI) tools, including large language models or machine learning software, were used in the preparation, analysis, or presentation of this manuscript.
References
- 1.Pascale A, Rosmorduc O, Duclos-Vallée JC. New epidemiologic trends in cholangiocarcinoma. Clin Res Hepatol Gastroenterol. 2023;47(9):102223. doi: 10.1016/j.clinre.2023.102223. [DOI] [PubMed] [Google Scholar]
- 2.Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. doi: 10.1038/s41575-020-0310-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Luvira V, Eurboonyanun Ch, Bhudhisawasdi V, Pugkhem A, Pairojkul Ch, Luvira V, Sathitkarnmanee E, Somsap K, Kamsa-ard S. Patterns of recurrence after resection of mass-forming type intrahepatic cholangiocarcinomas. Asian Pac J Cancer Prev. 2016;17(10):4735–4739. doi: 10.22034/apjcp.2016.17.10.4735. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–1122. doi: 10.1080/21645515.2019.1571892. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warrier S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, Scolyer RA, O’Toole SA. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 2016;69(1):25–34. doi: 10.1111/his.12904. [DOI] [PubMed] [Google Scholar]
- 6.Han Y, Liu D, Li L. PD-1/PD-L1 pathway: Current researches in cancer. Am J Cancer Res. 2020;10(3):727–742. [PMC free article] [PubMed] [Google Scholar]
- 7.Sangkhamanon S, Jongpairat P, Sookprasert A, Wirasorn K, Titapun A, Pugkhem A, Ungareevittaya P, Chindaprasirt J. Programmed death-ligand 1 (PD-L1) expression associated with a high neutrophil/lymphocyte ratio in cholangio-carcinoma. Asian Pac J Cancer Prev. 2017;18(6):1671–1674. doi: 10.22034/APJCP.2017.18.6.1671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Darvin P, Sasidharan Nair V, Elkord E. PD-L1 expression in human breast cancer stem cells is epigenetically regulated through posttranslational histone modifications. J Oncol. 2019;2019:3958908. doi: 10.1155/2019/3958908. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Takada K, Toyokawa G, Okamoto T, Shimokawa M, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y. A comprehensive analysis of programmed cell death ligand-1 expression with the clone SP142 antibody in non-small-cell lung cancer patients. Clin Lung Cancer. 2017;18(5):572–582.e1. doi: 10.1016/j.cllc.2017.02.004. [DOI] [PubMed] [Google Scholar]
- 10.Zhang J, Wu Z, Zhang X, Liu S, Zhao J, Yuan F, Shi Y, Song B. Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers. ESMO Open. 2020;5(6):e000910. doi: 10.1136/esmoopen-2020-000910. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chen F, Sheng J, Li X, Gao Z, Zhao S, Hu L, Chen M, Fei J, Song Z. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma. Biomed Pharmacother. 2024;175:116659. doi: 10.1016/j.biopha.2024.116659. [DOI] [PubMed] [Google Scholar]
- 12.Yu F, Gong L, Mo Z, Wang W, Wu M, Yang J, Zhang Q, Li L, Yao J, Dong J. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications. Biosci Trends. 2019;13(1):58–69. doi: 10.5582/bst.2019.01003. [DOI] [PubMed] [Google Scholar]
- 13.Xu G, Sun L, Li Y, Xie F, Zhou X, Yang H, Du S, Xu H, Mao Y. The clinicopathological and prognostic value of PD-L1 expression in cholangiocarcinoma: a meta-analysis. Front Oncol. 2019;9:897. doi: 10.3389/fonc.2019.00897. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Den K, Murakami T, Matsuyama R, Miyake K, Homma Y, Yabushita Y, Mori R, Hiroshima Y, Kato I, Endo I. Neoadjuvant chemoradiotherapy enhances tumor PD-L1 expression in pancreatic cancer. Anticancer Res. 2025;45(4):1731–1747. doi: 10.21873/anticanres.17554. [DOI] [PubMed] [Google Scholar]
- 15.Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) Nat Rev Gastroenterol Hepatol. 2016;13(5):261–280. doi: 10.1038/nrgastro.2016.51. [DOI] [PubMed] [Google Scholar]
- 16.Padthaisong S, Thanee M, Namwat N, Phetcharaburanin J, Klanrit P, Khuntikeo N, Titapun A, Sungkhamanon S, Saya H, Loilome W. Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma. J Transl Med. 2020;18(1):64. doi: 10.1186/s12967-020-02243-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–452. doi: 10.1016/j.immuni.2018.03.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024;23(1):108. doi: 10.1186/s12943-024-02023-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92. doi: 10.1186/s13045-019-0779-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Yamaguchi A, Saito Y, Okamoto K, Furugen A, Narumi K, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M, Kobayashi M. Association between multisystem immune-related adverse events and progression-free survivals in PD-1/PD-L1 inhibitor monotherapy. In Vivo. 2024;38(6):2886–2896. doi: 10.21873/invivo.13770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Li Y, He M, Zhou Y, Yang C, Wei S, Bian X, Christopher O, Xie L. The prognostic and clinicopathological roles of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis. Front Pharmacol. 2019;10:139. doi: 10.3389/fphar.2019.00139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Yu X, Li W, Liu H, Wang X, Coarfa C, Cheng C, Yu X, Zeng Z, Cao Y, Young KH, Li Y. PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. J Clin Invest. 2023;133(3):e160456. doi: 10.1172/JCI160456. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Kontomanolis E, Koutras A, Mitrakas AG, Trypsianis G, Nikolettos K, Tsikouras P, Nikolettos N, Giatromanolaki A, Koukourakis M. Tissue expression and plasma soluble PD-L1 levels in patients with endometrial cancer. Anticancer Res. 2024;44(12):5525–5530. doi: 10.21873/anticanres.17378. [DOI] [PubMed] [Google Scholar]
- 24.Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, Taplin ME, Choueiri TK, Hodi FS, Freeman GJ, Signoretti S. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26(4):812–817. doi: 10.1093/annonc/mdv009. [DOI] [PubMed] [Google Scholar]
- 25.Qin T, Zeng YD, Qin G, Xu F, Lu JB, Fang WF, Xue C, Zhan JH, Zhang XK, Zheng QF, Peng RJ, Yuan ZY, Zhang L, Wang SS. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget. 2015;6(32):33972–33981. doi: 10.18632/oncotarget.5583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023–5039. doi: 10.2147/OTT.S105862. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ishikawa M, Nakayama K, Nakamura K, Yamashita H, Ishibashi T, Minamoto T, Iida K, Razia S, Ishikawa N, Nakayama S, Otsuki Y, Kyo S. High PD-1 expression level is associated with an unfavorable prognosis in patients with cervical adenocarcinoma. Arch Gynecol Obstet. 2020;302(1):209–218. doi: 10.1007/s00404-020-05589-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kodali S, Connor AA, Brombosz EW, Ghobrial RM. Update on the screening, diagnosis, and management of cholangiocarcinoma. Gastroenterol Hepatol (N Y) 2024;20(3):151–158. [PMC free article] [PubMed] [Google Scholar]
- 29.Li Y, Song Y, Liu S. The new insight of treatment in Cholangiocarcinoma. J Cancer. 2022;13(2):450–464. doi: 10.7150/jca.68264. [DOI] [PMC free article] [PubMed] [Google Scholar]